Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial

World Journal of Gastroenterology

Volumn 23, Issue 1, 2017, Pages 141-150

  Joy, Tisha R ^a   McKenzie, Charles A ^a   Tirona, Rommel G ^a   Summers, Kelly ^a   Seney, Shannon ^a   Chakrabarti, Subrata ^a   Malhotra, Neel ^a   Beaton, Melanie D ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Hepatic steatosis; Insulin resistance; Magnetic resonance imaging; Non alcoholic steatohepatitis; Fibrosis; Nonalcoholic fatty liver disease; Platelet aggregation; Randomized controlled trial; Sitagliptin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; FATTY ACID; HEMOGLOBIN A1C; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SITAGLIPTIN; TRIACYLGLYCEROL; BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADIPOSE TISSUE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MALE; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; STEATOSIS; THROMBOCYTE AGGREGATION; THROMBOSIS; AGED; BIOPSY; BLOOD; DIAGNOSTIC IMAGING; FIBROSIS; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME; VALIDATION STUDY;

AGED; BIOMARKERS; BIOPSY; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FATTY ACIDS, NONESTERIFIED; FEMALE; FIBROSIS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PLACEBOS; PLATELET AGGREGATION; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME;

EID: 85011850239     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i1.141     Document Type: Article

References (42)

1. Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 16841-16857 [PMID: 25492998 DOI: 10. 3748/wjg. v20. i45. 16841]
2. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-690 [PMID: 24042449 DOI: 10. 1038/nrgastro. 2013. 171]
3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023 [PMID: 22488764 DOI: 10. 1002/hep. 25762]
4. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005; 42: 650-656 [PMID: 16037946 DOI: 10. 1002/hep. 20818]
5. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis 1970; 3: 371-407 [PMID: 4908707]
6. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29: 113-119 [PMID: 18384521 DOI: 10. 1111/j. 1478-3231. 2008. 01718. x]
7. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285 [PMID: 21623852 DOI: 10. 1111/j. 1365-2036. 2011. 04724. x]
8. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104 [PMID: 20578268 DOI: 10. 1002/hep. 23623]
9. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-1685 [PMID: 20427778 DOI: 10. 1056/NEJMoa0907929]
10. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB, Modi A, Nagabhyru P, Sumner AE, Liang TJ, Hoofnagle JH. Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2009; 29: 172-182 [PMID: 18945255 DOI: 10. 1111/j. 1365-2036. 2008. 03869. x]
11. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, Grimaldi A, Poynard T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebocontrolled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100-110 [PMID: 18503774 DOI: 10. 1053/j. gastro. 2008. 03. 078]
12. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Lenaour G, Hartmann-Heurtier A, Bruckert E, Poynard T. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology 2010; 51: 445-453 [PMID: 19877169 DOI: 10. 1002/hep. 23270]
13. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, DeFronzo R, Bannayan GA, Schenker S, Cusi K. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297-2307 [PMID: 17135584 DOI: 10. 1056/NEJMoa060326]
14. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, Guo K, Abouda G, Aldersley MA, Stocken D, Gough SC, Tomlinson JW, Brown RM, Hübscher SG, Newsome PN. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 2016; 387: 679-690 [PMID: 26608256 DOI: 10. 1016/S0140-6736(15)00803-X]
15. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013; 17: 819-837 [PMID: 23684623 DOI: 10. 1016/j. cmet. 2013. 04. 008]
16. Balaban YH, Korkusuz P, Simsek H, Gokcan H, Gedikoglu G, Pinar A, Hascelik G, Asan E, Hamaloglu E, Tatar G. Dipeptidyl peptidase IV (DDP IV) in NASH patients. Ann Hepatol 2007; 6: 242-250 [PMID: 18007554]
17. Firneisz G, Varga T, Lengyel G, Fehér J, Ghyczy D, Wichmann B, Selmeci L, Tulassay Z, Rácz K, Somogyi A. Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker. PLoS One 2010; 5: e12226 [PMID: 20805868 DOI: 10. 1371/journal. pone. 0012226]
18. Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, Barzilai N, Oren R, Fishman S. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMPactivated protein kinase. J Hepatol 2011; 54: 1214-1223 [PMID: 21145820 DOI: 10. 1016/j. jhep. 2010. 09. 032]
19. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zycband E, Moller DE, Thornberry NA, Zhang BB. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 2003; 100: 6825-6830 [PMID: 12748388 DOI: 10. 1073/pnas. 0631828100]
20. Onoyama T, Koda M, Okamoto T, Kishina M, Matono T, Sugihara T, Murawaki Y. Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice. Mol Med Rep 2015; 12: 6895-6902 [PMID: 26397061 DOI: 10. 3892/mmr. 2015. 4329]
21. Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets 2012; 23: 565-570 [PMID: 22950787 DOI: 10. 3109/0953 7104. 2012. 721907]
22. Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, Kaufman KD, Amatruda JM. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008; 8: 14 [PMID: 18954434 DOI: 10. 1186/1472-6823-8-14]
23. Migoya EM, Stevens CH, Bergman AJ, Luo WL, Lasseter KC, Dilzer SC, Davies MJ, Wagner JA, Herman GA. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009; 16: e165-e170 [PMID: 19221403]
24. Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitagliptin as a novel treatment agent for non-alcoholic Fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103-2105 [PMID: 22024083 DOI: 10. 5754/hge11263]
25. Yilmaz Y, Yonal O, Deyneli O, Celikel CA, Kalayci C, Duman DG. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. Acta Gastroenterol Belg 2012; 75: 240-244 [PMID: 22870790]
26. Cui J, Philo L, Nguyen P, Hofflich H, Hernandez C, Bettencourt R, Richards L, Salotti J, Bhatt A, Hooker J, Haufe W, Hooker C, Brenner DA, Sirlin CB, Loomba R. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial. J Hepatol 2016; 65: 369-376 [PMID: 27151177 DOI: 10. 1016/ j. jhep. 2016. 04. 021]
27. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10. 1002/ hep. 20701]
28. Reeder SB, Pineda AR, Wen Z, Shimakawa A, Yu H, Brittain JH, Gold GE, Beaulieu CH, Pelc NJ. Iterative decomposition of water and fat with echo asymmetry and least-squares estimation (IDEAL): application with fast spin-echo imaging. Magn Reson Med 2005; 54: 636-644 [PMID: 16092103 DOI: 10. 1002/mrm. 20624]
29. Reeder SB, Robson PM, Yu H, Shimakawa A, Hines CD, McKenzie CA, Brittain JH. Quantification of hepatic steatosis with MRI: the effects of accurate fat spectral modeling. J Magn Reson Imaging 2009; 29: 1332-1339 [PMID: 19472390 DOI: 10. 1002/ jmri. 21751]
30. Hines CD, Yu H, Shimakawa A, McKenzie CA, Brittain JH, Reeder SB. T1 independent, T2 corrected MRI with accurate spectral modeling for quantification of fat: validation in a fatwater-SPIO phantom. J Magn Reson Imaging 2009; 30: 1215-1222 [PMID: 19856457 DOI: 10. 1002/jmri. 21957]
31. Hines CD, Yu H, Shimakawa A, McKenzie CA, Warner TF, Brittain JH, Reeder SB. Quantification of hepatic steatosis with 3-T MR imaging: validation in ob/ob mice. Radiology 2010; 254: 119-128 [PMID: 20032146 DOI: 10. 1148/radiol. 09090131]
32. Meisamy S, Hines CD, Hamilton G, Sirlin CB, McKenzie CA, Yu H, Brittain JH, Reeder SB. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology 2011; 258: 767-775 [PMID: 21248233 DOI: 10. 1148/radiol. 10100708]
33. Al-Attar SA, Pollex RL, Robinson JF, Miskie BA, Walcarius R, Little CH, Rutt BK, Hegele RA. Quantitative and qualitative differences in subcutaneous adipose tissue stores across lipodystrophy types shown by magnetic resonance imaging. BMC Med Imaging 2007; 7: 3 [PMID: 17352814 DOI: 10. 1186/1471-2342-7-3]
34. Alabousi A, Al-Attar S, Joy TR, Hegele RA, McKenzie CA. Evaluation of adipose tissue volume quantification with IDEAL fat-water separation. J Magn Reson Imaging 2011; 34: 474-479 [PMID: 21780238 DOI: 10. 1002/jmri. 22603]
35. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, Mahmud E, Atar D, Serebruany V. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007; 119: 277-284 [PMID: 16563469 DOI: 10. 1016/j. thromres. 2006. 01. 019]
36. Cohen J. Statistical Power Analysis for the Behavioural Sciences. New Jersey: Lawrence Erlbaum Associates Inc. , 1988
37. Akaslan SB, Degertekin CK, Yilmaz G, Cakir N, Arslan M, Toruner FB. Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats. Metab Syndr Relat Disord 2013; 11: 243-250 [PMID: 23544853 DOI: 10. 1089/met. 2012. 0128]
38. Maiztegui B, Borelli MI, Madrid VG, Del Zotto H, Raschia MA, Francini F, Massa ML, Flores LE, Rebolledo OR, Gagliardino JJ. Sitagliptin prevents the development of metabolic and hormonal disturbances, increased ?-cell apoptosis and liver steatosis induced by a fructose-rich diet in normal rats. Clin Sci (Lond) 2011; 120: 73-80 [PMID: 20795946 DOI: 10. 1042/CS20100372]
39. Fukuhara T, Hyogo H, Ochi H, Fujino H, Kan H, Naeshiro N, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Chayama K. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014; 61: 323-328 [PMID: 24901133]
40. Arase Y, Kawamura Y, Seko Y, Kobayashi M, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Sezaki H, Saito S, Hosaka T, Ikeda K, Kumada H, Ohmoto-Sekine Y, Hsieh SD, Amakawa K, Ogawa K, Matsumoto N, Iwao A, Tsuji H, Hara S, Mori Y, Okubo M, Sone H, Kobayashi T. Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease. Hepatol Res 2013; 43: 1163-1168 [PMID: 23489256 DOI: 10. 1111/hepr. 12077]
41. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643 [PMID: 17130197 DOI: 10. 2337/dc06-0706]
42. Lima-Martínez MM, Paoli M, Rodney M, Balladares N, Contreras M, D'Marco L, Iacobellis G. Effect of sitagliptin on epicardial fat thickness in subjects with type 2 diabetes and obesity: a pilot study. Endocrine 2016; 51: 448-455 [PMID: 26233684 DOI: 10. 1007/s12020-015-0710-y]